17β-HSD

Cat. No.

A69065

CAS No.

2770247-94-2

HSD17B13-IN-89

HSD17B13-IN-89 is a potent inhibitor of 17β-Hydroxysteroid dehydrogenases (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol. This reagent is primarily utilized in research related to nonalcoholic fatty liver disease (NAFLD), offering valuable insights into the role of HSD17B13 in hepatic metabolism and disease progression. Its specificity and efficacy make it a critical tool for studying the pathophysiology of metabolic disorders.

Cat. No.

A69066

CAS No.

2770247-47-5

HSD17B13-IN-82

HSD17B13-IN-82 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for investigating the role of HSD17B13 in liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as in metabolic and cardiovascular disorders. Additionally, HSD17B13-IN-82 is useful for studying drug-induced liver injury (DILI) and its underlying mechanisms.

Cat. No.

A69067

CAS No.

1601-18-9

Indomethacin methylester

Synonyms: Indometacin methylester

Indomethacin methylester is a selective inhibitor of AKR1C3, exhibiting an IC50 of 5.67 μM. This compound is particularly relevant for studying its role in prostate cancer research, where it may aid in elucidating the mechanisms underlying tumor progression and therapeutic resistance. Its specificity for AKR1C3 offers potential insights into targeting this enzyme for cancer treatment strategies.

Cat. No.

A69068

CAS No.

2770247-40-8

HSD17B13-IN-71

HSD17B13-IN-71 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research targeting liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Additionally, HSD17B13-IN-71 can aid in investigations of drug-induced liver injury (DILI), making it a crucial tool in related biological studies.

Cat. No.

A69069

CAS No.

3075100-76-1

HSD17B13-IN-104

HSD17B13-IN-104 is a potent and selective inhibitor of HSD17B13, exhibiting an IC50 of 2.5 nM. This compound effectively modulates hepatic lipid metabolism by targeting the SREBP-1c/FAS signaling pathway, thereby reducing hepatic lipid accumulation. HSD17B13-IN-104 holds potential for advancing research on metabolic dysfunction-associated steatohepatitis and related conditions.

Cat. No.

A69070

CAS No.

2849338-41-4

HSD17B13-IN-95

HSD17B13-IN-95 is a potent inhibitor of 17 β-hydroxysteroid dehydrogenase (HSD17B13), with an IC50 value for estradiol of less than 0.1 μM. This compound is useful in the investigation of nonalcoholic fatty liver disease and other metabolic disorders associated with altered steroid hormone metabolism. Its ability to effectively modulate HSD17B13 activity makes it a valuable tool for research into the biological mechanisms underlying liver function and related pathologies.

Cat. No.

A69071

CAS No.

3004661-16-6

HSD17B13-IN-72

HSD17B13-IN-72 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of less than 0.1 μM for estradiol. This compound is valuable for studying the role of HSD17B13 in liver diseases and metabolic disorders, facilitating research into potential therapeutic interventions and mechanisms underlying these conditions. Its high specificity makes it an important tool for elucidating the biological pathways associated with steroid metabolism.

Cat. No.

A69072

CAS No.

2770246-37-0

HSD17B13-IN-24

HSD17B13-IN-24 is a potent inhibitor of 17β-Hydroxysteroid dehydrogenases (HSD17B13) with an IC50 value of less than 0.1 μM for estradiol. This compound is primarily utilized in research related to nonalcoholic fatty liver disease (NAFLD), facilitating the understanding of metabolic pathways and potential therapeutic targets in liver disorders. Its high specificity makes it a valuable tool for investigating the role of HSD17B13 in various biological contexts.

Cat. No.

A69073

CAS No.

2770247-58-8

HSD17B13-IN-55

HSD17B13-IN-55 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for investigating liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as metabolic and cardiovascular disorders. Additionally, it may support research into drug-induced liver injury (DILI), providing insights into its mechanisms and potential therapeutic interventions.

Cat. No.

A69074

CAS No.

2770247-26-0

HSD17B13-IN-61

HSD17B13-IN-61 is a specific inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of ≤ 0.1 μM for estradiol. This compound is intended for research into liver-related conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI), as well as various metabolic and cardiovascular diseases. Its high potency makes it a valuable tool for investigating the role of HSD17B13 in these disease contexts.

Cat. No.

A69075

CAS No.

2848620-81-3

HSD17B13-IN-90

HSD17B13-IN-90 is a selective inhibitor of 17β-Hydroxysteroid dehydrogenases, specifically targeting HSD17B13, with an IC50 of less than 0.1 μM for estradiol. This compound is employed in research related to nonalcoholic fatty liver disease (NAFLD), providing insights into the role of HSD17B13 in lipid metabolism and liver function. Its potent inhibitory activity makes it a valuable tool for investigating the biological effects of steroid hormone modulation in various pathological contexts.

Cat. No.

A69076

CAS No.

2758802-18-3

HSD17B13-IN-21

HSD17B13-IN-21 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol and less than 1 μM for leukotriene B3. This compound is significant in the study of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH). Its application in research could provide insight into the mechanisms underlying liver-related metabolic disorders.

Cat. No.

A69077

CAS No.

2758802-04-7

HSD17B13-IN-12

HSD17B13-IN-12 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of ≤ 0.1 μM for both leukotriene B3 and estradiol. This compound is valuable for studying liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its targeted inhibition offers insights into the biochemical pathways associated with these health issues.

Cat. No.

A69078

CAS No.

2770247-49-7

HSD17B13-IN-54

HSD17B13-IN-54 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for investigating the role of HSD17B13 in various pathologies, including liver diseases, metabolic disorders, and cardiovascular conditions such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Additionally, it serves as a useful tool for studying drug-induced liver injury (DILI).

Cat. No.

A69080

CAS No.

2849338-43-6

HSD17B13-IN-96

HSD17B13-IN-96 is a potent inhibitor of 17 β-hydroxysteroid dehydrogenase (HSD17B13), exhibiting an IC50 value for estradiol of less than 0.1 μM. This compound is primarily utilized in research focused on nonalcoholic fatty liver disease (NAFLD) and related metabolic disorders. Its effectiveness in modulating HSD17B13 activity provides valuable insights into the biological pathways involved in liver metabolism and pathology.

Cat. No.

A69081

CAS No.

2770246-39-2

HSD17B13-IN-25

HSD17B13-IN-25 is a specific inhibitor of 17β-Hydroxysteroid dehydrogenase type 13 (HSD17B13), demonstrating an IC50 of less than 0.1 μM for estradiol. This compound plays a significant role in the study of nonalcoholic fatty liver disease (NAFLD) by modulating steroid metabolism and fatty liver progression. Its application in preclinical research facilitates a deeper understanding of HSD17B13's involvement in lipid metabolism and liver pathology.

Cat. No.

A69082

CAS No.

2770246-31-4

HSD17B13-IN-79

HSD17B13-IN-79 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for investigating liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). HSD17B13-IN-79 serves as an important tool for research aimed at understanding the role of HSD17B13 in these pathological conditions.

Cat. No.

A69083

CAS No.

2848620-83-5

HSD17B13-IN-91

HSD17B13-IN-91 is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value for estradiol ranging between 0.1 μM and 0.5 μM. This compound is utilized in research contexts focusing on liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as metabolic disorders and cardiovascular diseases. Additionally, it is relevant for studying drug-induced liver injury (DILI), making it a valuable tool for understanding the role of HSD17B13 in various pathological conditions.

Cat. No.

A69084

CAS No.

2912459-67-5

HSD17B13-IN-77

HSD17B13-IN-77 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of less than 0.1 μM for estradiol. This compound is valuable for research related to liver diseases and metabolic disorders, providing insight into the role of HSD17B13 in various physiological and pathological processes. Its application may enhance understanding of steroid metabolism and its implications in health and disease.

Cat. No.

A69085

CAS No.

2919797-59-2

HSD17B13-IN-20

HSD17B13-IN-20 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). This compound plays a crucial role in the modulation of estrogen metabolism and is particularly relevant in the study of liver diseases, including hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma. HSD17B13-IN-20 provides valuable insights into the therapeutic targeting of HSD17B13 for the treatment and understanding of hepatic disorders.

Cat. No.

A69086

CAS No.

3004660-61-8

HSD17B13-IN-68

HSD17B13-IN-68 is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of less than 0.1 μM for estradiol. This compound is valuable for investigating the role of HSD17B13 in liver diseases and metabolic disorders, providing insights into potential therapeutic targets and mechanisms of action in these conditions. Its potency and specificity make it a useful tool for research in endocrinology and metabolic pathways.

Cat. No.

A69087

CAS No.

2770247-34-0

HSD17B13-IN-64

HSD17B13-IN-64 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research focused on liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as metabolic disorders and drug-induced liver injury (DILI). Its selective inhibition of HSD17B13 may provide insights into therapeutic strategies for these conditions.

Cat. No.

A69088

CAS No.

2915567-21-2

ESC1002755

ESC1002755 is a selective inhibitor of 17β-HSD10, exhibiting an IC50 of 19 nM and demonstrating non-competitive inhibition against the cofactor NADH. This compound shows minimal cytotoxicity in HEK293 cells at a concentration of 50 μM, making it a promising tool for studies related to Alzheimer’s disease and hormone-dependent cancers, including prostate, bone, and colorectal cancer. Research applications include exploring the enzymatic mechanisms and therapeutic interventions associated with these conditions.

Cat. No.

A69089

CAS No.

2758802-03-6

HSD17B13-IN-11

HSD17B13-IN-11 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting potent activity with an IC50 of ≤ 1 μM for leukotriene B3 and ≤ 0.1 μM for estradiol. This compound is valuable for investigating liver pathologies, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its role in metabolic and cardiovascular research also supports its utility in exploring potential therapeutic interventions.

Cat. No.

A69090

CAS No.

2730022-56-5

HSD17B13-IN-38

HSD17B13-IN-38 is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). This compound plays a significant role in the regulation of steroid metabolism and has potential implications in the study of liver and metabolic diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Researchers can utilize HSD17B13-IN-38 to explore its impact on cardiovascular diseases and related metabolic pathways.